-
A Breakthrough in Endometrial Cancer: New Chemotherapy-Free Treatment Shows Promise
A Shift in Cancer Care A landmark global Phase 3 clinical trial, led by a physician at Mount Sinai Medical Center, has unveiled encouraging results for patients with dMMR (mismatch repair deficient) endometrial cancer. The study demonstrates that a chemotherapy-free treatment regimen can significantly improve outcomes, marking a potential turning point in how this gynecological…
-
Understanding Inducement Grants: A Look at Nektar Therapeutics’ Recent Disclosure
NASDAQ: $NKTR What Are Inducement Grants? In the world of corporate governance, transparency is key. Recently, Nektar Therapeutics (NASDAQ: NKTR) issued a formal report regarding the granting of equity awards to new employees. These types of transactions are often referred to as inducement grants. The Details Behind the Disclosure On August 29, 2019, Nektar Therapeutics…
-
New Treatment Option: FDA Approves Subcutaneous Induction for Skyrizi in Crohn’s Disease
NYSE: $ABBV A New Milestone in Crohn’s Disease Management For adults living with moderately to severely active Crohn’s disease, there is a significant new development in treatment accessibility. The U.S. Food and Drug Administration (FDA) has officially approved a subcutaneous (SC) induction regimen for AbbVie’s Skyrizi (risankizumab-rzaa). What This Means for Patients Previously, patients often…
-
Advancing AAT Deficiency Treatment: Congruence Therapeutics Presents CGX-195
A New Frontier in AAT Deficiency Congruence Therapeutics has reached a significant milestone in its pursuit of novel therapies for Alpha-1 Antitrypsin (AAT) deficiency. The company recently announced that it will provide an oral presentation on its lead program, CGX-195, at the prestigious ERS Alpha-1 Antitrypsin (AAT) Conference 2026. Understanding CGX-195 CGX-195 is being developed…
-
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
NASDAQ: $REGN TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its potential to prevent lean mass and… Source: Read More
-
ImmunoForge Sets the Stage for Innovation at BIO-Europe 2026
Advancing the Future of Oncology As the global biotech community prepares for the upcoming BIO-Europe 2026 conference, ImmunoForge has announced its intention to showcase significant advancements in its therapeutic portfolio. The company is set to present its proprietary platform technologies and share critical updates regarding its next-generation oncology research and development efforts. Focusing on Clinical…
-
A New Hope in Lung Cancer: FDA Grants Fast Track Designation for TRE-515 Combination
Accelerating Progress in NSCLC Treatment The landscape of lung cancer treatment continues to evolve, with the FDA recently granting Fast Track designation to the investigational therapeutic combination involving TRE-515. This designation is a significant milestone for patients fighting non-small cell lung cancer (NSCLC), particularly those whose tumors harbor specific genetic mutations. The Role of KRAS…
-
A New Frontier in Cancer Therapy: GeorgiaMune and Menarini Join Forces
A Strategic Partnership in Immuno-Oncology The landscape of cancer treatment is evolving rapidly, and a recent announcement highlights a significant step forward. GeorgiaMune, a biotechnology company focused on innovative medical solutions, has entered into an exclusive global licensing and collaboration agreement with the Menarini Group. This partnership centers on the development of GIM-621, a promising…
-
A Breakthrough in Alzheimer’s Treatment: Solengepras Shows Promise in Phase 3 Trials
New Hope for Alzheimer’s Patients Cerevance recently announced promising results from its Phase 3 ARISE clinical trial, marking a potential turning point in the treatment of Alzheimer’s disease. The study evaluated the efficacy and safety of solengepras, a novel once-daily oral medication designed to address the progression of cognitive decline. Meeting Primary Endpoints The ARISE…
-
HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial
Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolumab alone, reducing the risk of disease progression or death by 27% Median progression-free survival was 11.7 months… Source: Read More
-
Zealand Pharma Announces Positive Phase 2 ZUPREME-2 Topline Results for Amylin Analog Petrelintide in People with Overweight or Obesity and Type 2 Diabetes
NASDAQ: $ZEAL Copenhagen, Denmark, October 7, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced positive topline results from the Phase 2 ZUPREME-2 trial… Source: Read More
-
Phylo’s Biomni Lab to expand the use of AI agents in scientific research at Bayer
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 /PRNewswire/ — Phylo, Inc. announced today a partnership with Bayer to deploy Biomni Lab, Phylo’s agentic AI platform to accelerate scientific research and evaluation. Under the agreement, Phylo will provide Bayer with full access to its agentic… Source: Read More
-
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
NASDAQ: $IRON WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious… Source: Read More
-
Viatris Receives U.S. FDA Approval for Ryzumvi for the Treatment of Presbyopia
NASDAQ: $VTRS PITTSBURGH, Oct. 16, 2026 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Ryzumvi (phentolamine ophthalmic solution 0.75%) for the treatment of… Source: Read More
-
Vanda Pharmaceuticals Sets Date for Q3 2026 Financial Results
NASDAQ: $VNDA Mark Your Calendars: Q3 2026 Financial Update Vanda Pharmaceuticals Inc. has officially announced that it will release its financial results for the third quarter of 2026 on Wednesday, October 28, 2026. This upcoming disclosure is a key event for investors and stakeholders looking to gauge the company’s performance throughout the quarter. How to…
-
EyePoint Pharmaceuticals Announces Positive Topline Results for DURAVYU in Wet AMD
NASDAQ: $EYPT A Major Milestone in Retinal Disease Treatment EyePoint Pharmaceuticals has officially announced the topline results from its LUCIA study, the second pivotal Phase 3 clinical trial evaluating the efficacy and safety of DURAVYU (vorolanib) for the treatment of wet age-related macular degeneration (wet AMD). Understanding the LUCIA Trial Results The LUCIA trial was…
-
Clearer Eyes Ahead: FDA Approves Upneeq (Apraclonidine) for Eye Redness
NYSE: $ALC A New Solution for Eye Redness Dealing with persistent eye redness can be frustrating, often affecting both comfort and appearance. Recently, the FDA provided a new option for patients by approving Upneeq (apraclonidine hydrochloride ophthalmic solution), a prescription eye drop designed to address this common concern. What You Should Know About Upneeq Upneeq…
-
Fresenius Medical Care Enhances Critical Care with the U.S. Launch of multiFiltratePRO
A New Standard in Intensive Care Kidney Support Fresenius Medical Care, a global leader in renal care, has officially announced the U.S. launch of the multiFiltratePRO. This innovative system is designed to provide life-sustaining kidney replacement therapy for patients in critical care settings, marking a significant advancement in how hospitals manage acute kidney injury (AKI).…
-
XBiotech Reports Positive Phase II Results in Investigator-Sponsored TASKIN Trial
NASDAQ: $XBIT A New Milestone in Clinical Research XBiotech Inc. has announced positive final efficacy results from the investigator-sponsored TASKIN trial. This Phase II clinical study marks a significant step forward in the company’s efforts to evaluate the potential of its therapeutic candidates in a clinical setting. Understanding the TASKIN Trial The TASKIN trial was…
-
New Treatment Option: Cosette Pharmaceuticals Receives FDA Approval for Evoxac Oral Solution
A New Milestone in Dry Mouth Treatment Patients suffering from the symptoms of Sjogren’s syndrome now have a new way to manage their condition. Cosette Pharmaceuticals, Inc. has officially announced that the U.S. Food and Drug Administration (FDA) has granted approval for Evoxac (cevimeline HCl) oral solution (15 mg/5 mL). This approval marks an important…
-
Genomma Lab Internacional Announces Results for the Third Quarter 2026
MEXICO CITY, Oct. 21, 2026 /PRNewswire/ — Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma” or “the Company”), today announced its results for the third quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with… Source: Read More
-
Novo’s CagriSema Was Associated with 25% Weight Loss on Average for Women in a Post Hoc Analysis of REDEFINE 1
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Oct. 20, 2026 /PRNewswire/ — Today, Novo announced results from two post hoc analyses of the REDEFINE 1 trial presented at The Menopause Society 2026 Annual Meeting in San Diego. In an analysis of… Source: Read More
-
New Hope for Chronic Hepatitis B: Understanding the FDA Approval of Hepcludex (bepirovirsen)
NYSE: $GSK A Significant Milestone in Liver Health The landscape of chronic hepatitis B (CHB) treatment is evolving. Recently, the FDA reached a significant decision regarding Hepcludex (bepirovirsen), providing new options for patients managing this complex viral infection. This development marks a noteworthy step forward in therapeutic approaches for those living with chronic liver disease.…
-
Early LGS-CORE Registry Data Show Only 4% of Reported Treatments Stopped All Seizures in Lennox-Gastaut Syndrome
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ — The Lennox-Gastaut Syndrome (LGS) Foundation will present the first data from its LGS Collaborative Outcomes Registry (LGS-CORE) at the 2026 NORD Rare Diseases & Orphan Products Breakthrough Summit, October 25 to 27 in Washington, DC. LGS-CORE is a… Source: Read More
-
Breakthrough Results: Encaleret Shows Promise for Autosomal Dominant Hypocalcemia Type 1
NASDAQ: $BBIO A New Frontier in Treating ADH1 Recent results from the Phase 3 CALIBRATE trial have brought a wave of optimism for patients living with Autosomal Dominant Hypocalcemia Type 1 (ADH1). The trial evaluated the efficacy and safety of encaleret, an investigational therapy designed to address the underlying physiological challenges of this rare genetic…